Alnylam

Alnylam

Alnylam

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi.
Type
B2c
Founded
2002
Raised
$710M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
$700,000,000
Post-IPO equity - 2014
Genzyme
$10,000,000
Venture capital - 2011
Takeda Pharmaceutical
Team Size
200+
Employees
neurons.AI

Key Vendors of Huntingtons Disease Therapeutics Market: Alnylam Pharmaceuticals, Intellect …

Xconomy

Bio Roundup: Alnylam's Billions, COVID-19 Vaccines, Moma Debuts & More

Xconomy

Blackstone Pays Alnylam $1B to Grab a Stake in RNAi Drug Inclisiran

FinSMEs

Alnylam To Receive $2 Billion Financing from Blackstone

Xconomy

Alnylam Gets Quick FDA OK for Second RNAi Rare Disease Drug

Xconomy

Alnylam Gets $800M From Regeneron to Bring RNAi to Eye, Brain Diseases

Xconomy

Data in Hand, Alnylam To Seek OK For Second RNAi Drug

Xconomy

Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug

Xconomy

FDA OKs Akcea Rare Disease Drug, Setting Up Market Clash with Alnylam

Xconomy

With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug

Xconomy

RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug

Xconomy

Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision

Health Science
Xconomy

Ionis Sends Nerve Drug to Spinout Akcea as Battle with Alnylam Looms

Robotics Health Strategy
Xconomy

In Week of Hemophilia News, Alnylam Drug Cleared to Move Forward

Robotics Health
Xconomy

Alnylam Data Puts a Nobel Discovery One Step Closer to Approved Drug

Health Science
Xconomy

On Eve of Big Data Reveal, Patient Death Stalls Alnylam Hemophilia Drug

Health
Xconomy

Bio Roundup: Theranos Cuts, Alnylam Stops, Nobel Eats Its Own & More

Health Science
Xconomy

Alnylam Scraps RNAi Drug After Safety Problems, Shares Plunge

Health
The Motley Fool

Why Alnylam Pharmaceuticals, Inc. Competed Higher Today

Health
The Motley Fool

Better Buy: Alnylam Pharmaceuticals, Inc. vs. Ionis Pharmaceuticals Inc.